<DOC>
	<DOCNO>NCT01157871</DOCNO>
	<brief_summary>The primary objective ass safety efficacy two different dos NV1FGF compare placebo . The secondary objective ass pharmacokinetics NV1FGF FGF-1 protein .</brief_summary>
	<brief_title>Dose-finding , Safety Efficacy Study NV1FGF Patients With Intermittent Claudication</brief_title>
	<detailed_description>Screening 1 4 week study drug administration ; 6 week treatment , follow 20 week follow-up .</detailed_description>
	<mesh_term>Intermittent Claudication</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>Inclusion criterion : Age &gt; 40 year History typical intermittent claudication last least 3 month , show improvement consistent treadmill test finding Objective evidence Peripheral Arterial Occlusive Disease . After 10 minute rest , either Ankle brachial index measure ( ABI ) &lt; 0.8 Systolic ankle pressure ( AP ) &lt; 50 mmHg Systolic toe pressure &lt; 50 mmHg Patent femoral inflow level injection recently ( &lt; 2 week ) document either Doppler ultrasonography Magnetic Resonance Angiography Angiography Exclusion criterion : Evidence cause leg pain intermittent claudication . Illnesses limit subject exercise capacity ( angina pectoris , heart failure , respiratory disease , orthopaedic disease , neurological disorders… ) Pain rest Buerger 's disease Positive serology HIV 1 2 , positive serology hepatitis B C. Subjects serum creatinine &gt; 2 mg/dl ( 176 µmol/l ) subject dialysis . Active proliferative retinopathy define presence new vessel formation scar . Subjects stroke neurologic deficit presume due stroke within 3 month prior first administration study treatment Previous treatment angiogenic growth factor Pregnant breast feed woman disagree practice medically accept method birth control . Men woman agree use condom accept protection barrier , entire study period Serious concomitant medical condition adequately control . Current alcohol drug abuse The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>